Grape King Bio Ltd. posted record third-quarter earnings as Taiwan’s largest probiotics maker benefited from robust domestic sales despite headwinds in mainland China.
Net income climbed 18% to NT$750 million ($23.8 million) from a year earlier, while earnings per share reached NT$2.81. Revenue for October rose 7% to NT$880 million, extending the company’s growth streak.
The Taiwanese manufacturer’s home market operations showed particular strength, with October sales surging 14% year-over-year, driven by orders from major domestic clients and pharmaceutical segment growth. The company said its order book now extends into the first quarter of 2025.
However, the firm’s Shanghai unit faced challenges during China’s Singles’ Day shopping festival, with softer customer demand affecting its contract manufacturing business. To counter this slowdown, the company plans to diversify operations through new channels and launch health-focused snack products.
Grape King is pushing into functional beverages with its Combate 200P EX drink line and special edition Kombucha products, while expanding its e-commerce presence to boost sales growth.
